The Unicorn Co. — Analyst Briefing

The shortage is real and acute right now

U.S. whey protein is in a genuine physical shortage, not merely an expensive market. As of early 2026, WPC80 trades near $10.50/lb and WPI near $12.75/lb — both at or near record highs, roughly 3–4× pre-2024 levels. Producers have sold forward into and beyond 2026; new buyers report product is effectively unavailable at any price. The procurement pain in the source documents is not bad luck — it is the market. HIGH confidence

GLP-1 is structurally lifting protein demand

Roughly 10M Americans — about 12% of adults — are on a GLP-1 drug, and adoption is still accelerating (oral formulations, widening employer coverage), with credible projections of 25–30M users by 2030. Because GLP-1 users lose lean muscle alongside fat, clinical guidance pushes elevated protein intake, and the food industry is now explicitly building protein-dense products for them. One caveat kept honest: GLP-1 users also eat less total food, so the shift is toward protein density per calorie, not unbounded protein volume. HIGH confidence

How long does the shortage last?

Whey is a commodity, and commodities mean-revert. Roughly $11 billion across ~53 new and expanded U.S. dairy-processing facilities is scheduled online by 2028, including major new WPI capacity. New protein-fractionation lines take ~2–4 years to build. The base-case read: tightness persists through 2026–2027 with high confidence; the market approaches equilibrium around 2028–2029. Treat the favourable window as ~2–3 years — durable enough to build a business, not permanent enough to coast on. MODERATE confidence on timing

Pivot the product to A2 buffalo casein / MPC

This is the correct correction — but it is a smaller, harder business, not a save. Three things must be said plainly:

• The market is smaller. Global MPC is ~$3–3.5B and micellar casein ~$1–1.6B — together roughly 3–5× smaller than whey, growing at mid-single digits.
• There is no price premium. Casein and MPC trade roughly on par with whey; MPC currently at a slight discount. The pivot fixes the science, not the economics.
• Buffalo MPC has a real processing defect. Documented buffalo milk protein concentrate shows poor dispersibility (7–63%) and solubility (24–67%) — caused by the very calcium-and-casein richness that makes buffalo milk attractive. This hurts a casein/MPC product more than it would a whey one, because solubility is exactly what MPC is sold on.

Colombia cannot make this today

Colombia has a real and growing water-buffalo herd (~617,000 head in 2025) and a genuine buffalo-cheese cluster in the Caribbean region — but every named Colombian buffalo dairy company is a cheese and mozzarella producer (DIBUFALA, BUF Creamery, Bufala Grande, COLANTA's buffalo line). The country has only a handful of cow-milk powder dryers and no whey, casein or MPC fractionation capacity for buffalo milk anywhere. Sports-nutrition-grade protein ingredient manufacture — ultrafiltration, controlled spray-drying, NSF / Informed-grade certification — does not exist in the Colombian buffalo segment. HIGH confidence

The roadmap's volumes collide with physical milk supply

Producing 80%-protein powder consumes milk: about 21 litres per kg as MPC, but about 290 litres per kg as whey (whey is only 11% of buffalo milk protein). At the roadmap's ~400 MT/yr target, a casein/MPC product needs ~8.5M litres — a meaningful but conceivable share of national buffalo milk. The same target as whey needs ~115M litres — roughly the entire optimistic estimate of Colombia's national buffalo-milk output. The roadmap's Section 11 figure (3,120 MT/yr) is milk-balance-impossible under every interpretation.

Colombian national buffalo-milk output is poorly documented; estimates span widely (~20–130M L/yr). This compounds the risk rather than relieving it. LOW confidence on the national figure — itself a diligence item

The source documents frame this as near-virgin whitespace. It is not. Buffalo whey protein already ships commercially (B-Power, Italy); A2 protein powder already sits on U.S. shelves (Erewhon, Alexandre Family Farm); Colombian buffalo dairy is already in U.S. retail (Annabella, BUF Creamery). The defensible claim is narrow and specific — exclusivity on a Colombian-origin A2 buffalo casein/MPC — not "buffalo protein," and not "A2," as a category.

The "Made with Unicorn" model has no precedent for a base protein

The plan models itself on branded ingredients like "Made with KSM-66." That model is real and powerful — but the winners (KSM-66 ashwagandha, Creapure creatine, Cognizin) are novel functional actives backed by dozens of clinical trials, built over 5–10 years with $1M+ of clinical and regulatory spend. In protein specifically, the dairy "brands" — Glanbia's Provon, Arla's Lacprodan — are B2B ingredient grades, not consumer on-pack logos; formulators treat them as substitutable. The on-pack ingredient brands that do exist around protein are functional add-ons (digestive enzymes, absorption boosters), not the protein itself. No branded base protein has achieved consumer pull-through. MODERATE–HIGH confidence

If Unicorn pursues an ingredient brand, it must behave like a novel-active company

That means: commission a clinical study (A2 digestibility / sustained-release in a clinical population), pursue the certifications, and budget 5–10 years and seven figures for the brand build — not the roadmap's 24-month, ~$1.5M plan, which is sized for a distributor, not an ingredient brand. The realistic near-term posture is a quiet B2B ingredient supplier first, earning the right to an on-pack brand later, once a substantiated claim exists.

The original target list (verified — all real companies) remains usable; what changes is the order. Clinical nutrition moves from a "Phase 3" afterthought to the lead segment, because it is the one channel where the product's real weakness does not bite.

Below is the complete target-customer roster drawn from the source research — roughly 60 named U.S. companies across six segments, all verified as real businesses. Within each segment, accounts are tiered: Tier 1 / Anchor = sign as an on-pack co-branded partner; Tier 2 = commercial volume, less marketing leverage; Tier 3 = smaller volume, story-building or door-opening value.

One change from the source documents: the segment priority order is revised for the A2 casein/MPC pivot. Clinical / medical nutrition moves to the lead position; clear-format functional beverage is deferred until buffalo MPC's solubility is proven. The roster itself is unchanged and complete — keep every name on the list; only the sequence of attack changes.

Highest margins; A2 casein addresses real clinical GI-tolerance, sarcopenia and post-bariatric needs; sustained-release casein is the point, and the channel tolerates buffalo MPC's solubility weakness. Long sales cycles, very sticky.

Consumer base already educated on A2 and digestive tolerance — buffalo A2 is a credibility-stacking line extension, not a new category to teach.

Pay premium ingredient prices and market on ingredient quality. Under the casein/MPC pivot, target their night-time / sustained-release SKUs rather than clear cold-mix isolates.

CMOs are gatekeepers to hundreds of downstream brands. Land 2–3 as a "preferred A2 source" and the ingredient quietly shows up in dozens of formulations — but only pursue once a COA history and stable specs exist.

Already understand and pay for buffalo milk. Natural buyers — and possible future competitors. Approach the closest analogues as co-development partners before they become rivals.

High-growth and high-margin — but clear, cold-mixed RTD formats are exactly where buffalo MPC's solubility defect is disqualifying. Keep the list warm; do not pursue until processing is proven. Revisit as a Phase 3+ opportunity.

The phase run-rates (60 / 160 / 280 / 380 MT/yr) are internally consistent and match the credible exec-summary path — they are the figures the broken Section 11 model should have used.